Infant Bacterial Therapeutics AB (OSTO:IBT B) Total Assets : kr207.92 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Total Assets?

Infant Bacterial Therapeutics AB's Total Assets for the quarter that ended in Mar. 2025 was kr207.92 Mil.

During the past 12 months, Infant Bacterial Therapeutics AB's average Total Assets Growth Rate was -58.80% per year. During the past 3 years, the average Total Assets Growth Rate was -9.40% per year. During the past 5 years, the average Total Assets Growth Rate was -7.70% per year. During the past 10 years, the average Total Assets Growth Rate was -0.90% per year.

During the past 11 years, Infant Bacterial Therapeutics AB's highest 3-Year average Total Assets Growth Rate was 17.10%. The lowest was -17.80%. And the median was -2.65%.

Total Assets is connected with ROA %. Infant Bacterial Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2025 was -29.93%. Total Assets is also linked to Revenue through Asset Turnover. Infant Bacterial Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2025 was 0.00.

Infant Bacterial Therapeutics AB Total Assets Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Total Assets Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

450.32

408.48

349.62

351.33

239.57

Infant Bacterial Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Assets	Get a 7-Day Free Trial															348.88	296.44	239.30	239.57	207.92

Infant Bacterial Therapeutics AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Infant Bacterial Therapeutics AB's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	170.263	+	69.303
	=	239.57

Infant Bacterial Therapeutics AB's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2025 )	+	Total Liabilities (Q: Mar. 2025 )
	=	153.524	+	54.392
	=	207.92

Infant Bacterial Therapeutics AB (OSTO:IBT B) Total Assets Explanation

Total Assets is connected with ROA %.

Infant Bacterial Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %	=	Net Income (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	-66.956	/	( (239.566	+	207.916)	/ 2 )
	=	-66.956	/	223.741
	=	-29.93 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Infant Bacterial Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2025 is

	Asset Turnover
=	Revenue (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
=	0	/	( (239.566	+	207.916)	/ 2 )
=	0	/	223.741
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Infant Bacterial Therapeutics AB Total Assets Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines